Montelimar

Colorectal cancer mainly affects elderly patients, with over half of new cases in France occurring in those aged 70 or older. Adjuvant chemotherapy has shown benefits in disease-free and overall survival after stage III colon cancer surgery, but its use in elderly patients remains limited. This phase III randomized study explores whether adjuvant chemotherapy improves disease-free survival in elderly patients and which chemotherapy regimen is most effective, addressing concerns about benefits for both unfit and fit elderly patients. Participants will be divided into two groups based on a multidisciplinary evaluation including a geriatrician. One group will receive fluoropyrimidine-based chemotherapy (LV5FU2 or capecitabine), and the other will receive oxaliplatin-based chemotherapy (FOLFOX4 or XELOX). Some patients may be assigned to observation only. Treatments will begin within 12 weeks after surgery. The study also evaluates specific biological markers common in elderly tumors, such as mismatch repair deficiency. During the study, participants will undergo assessments including geriatric questionnaires and medical monitoring. Researchers will track disease-free survival over three years following the last patient's enrollment. Safety and treatment effects will be monitored, with exclusion of patients expected to live less than four years or those unable to comply with follow-up. The study aims to better understand chemotherapy benefits in an elderly population after colon cancer surgery.

Researchers are evaluating the addition of a therapeutic education program combined with nursing phone follow-up compared to conventional management alone in women with non-metastatic breast cancer undergoing adjuvant hormone therapy. The study aims to reduce the impact of side effects from hormone therapy and improve patients' quality of life during the first year of treatment through personalized and coordinated care. Participants who receive the therapeutic education and nursing support program will attend an initial educational assessment around the start of their hormone therapy. They will work with a nurse to set personalized goals and choose relevant workshops as part of an outpatient educational program. This is offered alongside the usual oncology follow-up care. Throughout the first year, patients will be monitored for management of side effects related to hormone therapy. The study collects adverse event information and questionnaire responses via an online platform. The main outcome is to compare how well the education program with nursing phone follow-up manages these side effects versus conventional treatment alone over one year.